Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Local Stocks
Buffalo Local Index
Buffalo Local Index
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Articles published by Sierra Oncology
Sierra Oncology Announces Submission of New Drug Application for Momelotinib to US Food & Drug Administration
June 17, 2022
From
Sierra Oncology
Via
Business Wire
Tickers
SRRA
Momelotinib Pivotal Phase 3 Data Receives Oral Presentation at American Society of Clinical Oncology Annual Meeting
May 26, 2022
From
Sierra Oncology
Via
Business Wire
Tickers
SRRA
Sierra Oncology Announces Oral Presentation of Momelotinib Pivotal Phase 3 Data at European Hematology Association Annual Meeting
May 12, 2022
From
Sierra Oncology
Via
Business Wire
Tickers
SRRA
Sierra Oncology Reports First Quarter 2022 Results
May 06, 2022
From
Sierra Oncology
Via
Business Wire
Tickers
SRRA
Sierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
May 05, 2022
From
Sierra Oncology
Via
Business Wire
Tickers
SRRA
GSK Reaches Agreement to Acquire Late-Stage Biopharmaceutical Company Sierra Oncology For $1.9bn
April 13, 2022
From
Sierra Oncology
Via
Business Wire
Tickers
SRRA
Sierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
April 06, 2022
From
Sierra Oncology
Via
Business Wire
Tickers
SRRA
Sierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
February 18, 2022
From
Sierra Oncology
Via
Business Wire
Tickers
SRRA
Sierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
February 04, 2022
From
Sierra Oncology
Via
Business Wire
Tickers
SRRA
Sierra Oncology Announces Full Exercise of Underwriters’ Option to Purchase Additional Shares
February 03, 2022
From
Sierra Oncology
Via
Business Wire
Tickers
SRRA
Sierra Oncology to Participate in Guggenheim Oncology Conference
February 03, 2022
From
Sierra Oncology
Via
Business Wire
Tickers
SRRA
Sierra Oncology Announces Closing of Upsized Public Offering of $135.0 Million of Securities
January 31, 2022
From
Sierra Oncology
Via
Business Wire
Tickers
SRRA
Sierra Oncology to Present at B. Riley Securities Oncology Investor Conference
January 27, 2022
From
Sierra Oncology
Via
Business Wire
Tickers
SRRA
Sierra Oncology Announces Pricing of Upsized Public Offering of Securities
January 26, 2022
From
Sierra Oncology
Via
Business Wire
Tickers
SRRA
Sierra Oncology Announces Proposed Public Offering of Common Stock
January 25, 2022
From
Sierra Oncology
Via
Business Wire
Tickers
SRRA
Sierra Oncology Provides Financial Update to Support the Future Commercialization of Momelotinib
January 25, 2022
From
Sierra Oncology
Via
Business Wire
Tickers
SRRA
Sierra Oncology Announces Momelotinib Achieved Statistically Significant Benefit on Symptoms, Anemia and Splenic Size in the Pivotal MOMENTUM Study for Myelofibrosis
January 25, 2022
From
Sierra Oncology
Via
Business Wire
Tickers
SRRA
Momelotinib Review Article Published in Journal of Hematology & Oncology Highlights Importance of Anemia Benefit for Myelofibrosis Patients
January 19, 2022
From
Sierra Oncology
Via
Business Wire
Tickers
SRRA
Sierra Oncology Updates Topline Data Timing for Pivotal Phase 3 Trial of Momelotinib in Myelofibrosis
January 18, 2022
From
Sierra Oncology
Via
Business Wire
Tickers
SRRA
Sierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
January 07, 2022
From
Sierra Oncology
Via
Business Wire
Tickers
SRRA
Sierra Oncology Reports Baseline Ferritin Differentially Predicts Week 24 Transfusion Independence Response in Myelofibrosis Patients
December 13, 2021
From
Sierra Oncology
Via
Business Wire
Tickers
SRRA
Sierra Oncology Announces Investor Event to Review MOMENTUM Trial Design and Available Phase 3 Momelotinib Data in Myelofibrosis
December 06, 2021
From
Sierra Oncology
Via
Business Wire
Tickers
SRRA
Sierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
December 03, 2021
From
Sierra Oncology
Via
Business Wire
Tickers
SRRA
Sierra Oncology Announces Presentation at Jefferies London Healthcare Conference
November 12, 2021
From
Sierra Oncology
Via
Business Wire
Tickers
SRRA
Sierra Oncology Reports Third Quarter 2021 Results
November 05, 2021
From
Sierra Oncology
Via
Business Wire
Tickers
SRRA
Sierra Oncology Announces Momelotinib Poster Accepted for Presentation at ASH
November 04, 2021
From
Sierra Oncology
Via
Business Wire
Tickers
SRRA
Sierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
November 03, 2021
From
Sierra Oncology
Via
Business Wire
Tickers
SRRA
Sierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
October 04, 2021
From
Sierra Oncology
Via
Business Wire
Tickers
SRRA
Sierra Oncology to Present at Three September Investor Conferences
September 07, 2021
From
Sierra Oncology
Via
Business Wire
Tickers
SRRA
Sierra Oncology Announces Inducement Grants Under NASDAQ Listing Rule 5635(c)(4)
September 03, 2021
From
Sierra Oncology
Via
Business Wire
Tickers
SRRA
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.